hsa-mir-6126: Hsa-mir-6126 is a miRNA that has been found to be upregulated in various studies [PMC8712139]. It has been identified as one of the most abundant miRNAs in C92EVSEC [PMC8145507]. In a comparison of different time points, hsa-mir-6126 was found to be differentially expressed [PMC8005181]. It has also been used as a miRNA mimic in experiments [PMC8258628]. Hsa-mir-6126, along with other miRNAs, was found to be expressed at low levels in the sera of pancreatic ductal adenocarcinoma (PDAC) patients but not in controls, suggesting its potential as a biomarker for this cancer type [PMC8301411]. Hsa-mir-6126 has been associated with long-term survival in PDAC patients [PMC8301411] and has also been identified as one of the most significantly increased miRNAs in the plasma of PDAC patients [PMC8301411] and associated with long-term survival along with hsa-miR-486-5p and hsa-miR-3135b [PMC8833770]. However, there is limited information available on the association between hsa-mir-6126 and cancer progression or survival [PMC8301411]. In addition to hsa-mir-6126, other circulating miRNAs have also shown potential as biomarkers for PDAC when expressed at low levels only in patient sera and not controls [PMC8301411].